Furthermore, mutation of the homologous Tyr931 in JAK2 wild - type or JAK2 V617F mutant found in patients with myeloproliferative neoplasms also conferred resistance to JAK inhibitors, such as INCB018424, which is currently in clinical use. (haematologica.org)
Contemporary Management of Myeloproliferative Neoplasms Brady L. Stein and Brandon J. McMahon, Eds. (sciencemag.org)
Dr. Nguyen's research is focused on developing novel therapy to treat myeloproliferative neoplasms, particularly for patients with myelofibrosis and mast cell disease. (uofmhealthblogs.org)